8-K: Marinus Pharmaceuticals Completes Enrollment in Phase 3 TrustTSC Trial and Secures New Patent for Ganaxolone

Marinus Pharmaceuticals has completed enrollment in its Phase 3 TrustTSC trial for ganaxolone in Tuberous Sclerosis Complex and secured a new method of use patent.

Summary

• Marinus Pharmaceuticals has completed enrollment in the global Phase 3 TrustTSC trial, which is evaluating oral ganaxolone for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC) in children and adults.
• The TrustTSC trial enrolled patients with highly refractory TSC who experienced significant seizure burden despite treatment with multiple antiseizure medications, including mTOR inhibitors.
• The titration schedule of ganaxolone was modified in the Phase 3 trial to reduce somnolence-related adverse events and improve patient response, with less than 2% of participants discontinuing due to these events.
• Topline data from the TrustTSC trial is expected in the first half of the fourth quarter of 2024.
• Marinus is targeting a supplemental New Drug Application submission to the FDA in April 2025, requesting priority review.
• The United States Patent and Trademark Office (USPTO) has granted Marinus a new method of use patent for ganaxolone in the treatment of TSC, expiring in 2040, which is the company's second such patent for ganaxolone in TSC.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of enrollment in a Phase 3 trial, the granting of a new patent, and the improved tolerability of the drug. However, the risks section tempers the overall sentiment.

Positives

• The completion of enrollment in the Phase 3 TrustTSC trial is a significant milestone for the company.
• The modified titration schedule of ganaxolone has shown improved tolerability, with a low discontinuation rate due to somnolence.
• The granting of a new method of use patent strengthens the company's intellectual property position for ganaxolone in TSC.
• The trial included patients with highly refractory TSC, addressing a significant unmet medical need.
• The company is targeting a supplemental New Drug Application submission to the FDA in April 2025 with priority review requested.

Risks

• The company's ability to continue as a going concern is a risk.
• Unexpected actions by the FDA or other regulatory agencies could impact the company's products and product candidates.
• There are risks associated with the design, enrollment, completion, and results of clinical trials.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Clinical trial results may not support regulatory approval or further development.
• Delays, interruptions or failures in the manufacture and supply of product candidates could occur.
• The company's ability to obtain additional funding to support its clinical development and commercial programs is a risk.

Future Outlook

Marinus anticipates topline data from the TrustTSC trial in the first half of Q4 2024 and plans to submit a supplemental New Drug Application to the FDA in April 2025, requesting priority review. The company also intends to continue investing in both IV and oral formulations of ganaxolone.

Management Comments

• Alex Aimetti, Ph.D., Chief Scientific Officer, stated that they are pleased to have completed enrollment in the pivotal Phase 3 trial in tuberous sclerosis complex.
• Joseph Hulihan, M.D., Chief Medical Officer, noted that the titration schedule of ganaxolone was modified in the Phase 3 TrustTSC trial to reduce somnolence-related adverse events and improve patient response.

Industry Context

This announcement is significant in the context of the pharmaceutical industry's focus on developing treatments for rare diseases like Tuberous Sclerosis Complex. The completion of enrollment in a Phase 3 trial and the granting of a new patent are positive steps for Marinus in this competitive landscape.

Comparison to Industry Standards

• The TrustTSC trial is notable for being the first controlled trial in TSC to allow enrollment of participants taking a full range of concomitant medications, including everolimus and cannabidiol, which is a departure from typical trial designs.
• The modification of the ganaxolone titration schedule to improve tolerability is a key differentiator, as somnolence is a common side effect of many antiseizure medications.
• The granting of a second method of use patent for ganaxolone in TSC further strengthens Marinus's position in the market compared to competitors who may not have similar intellectual property protection.

Stakeholder Impact

• Shareholders will likely view the completion of enrollment and the new patent as positive developments.
• Patients with TSC and their families may benefit from a new treatment option.
• Employees of Marinus will be involved in the next steps of the clinical trial and regulatory submissions.
• The company's suppliers and partners may see increased activity as the company progresses.

Next Steps

• Marinus will analyze the data from the TrustTSC trial.
• The company will prepare for the release of topline data in the first half of Q4 2024.
• Marinus will submit a supplemental New Drug Application to the FDA in April 2025.
• The company will continue to invest in the development of ganaxolone in both IV and oral formulations.

Key Dates

Keywords

Ganaxolone, Tuberous Sclerosis Complex, TSC, Seizures, Phase 3 Trial, TrustTSC, Patent, FDA, Clinical Trial, Epilepsy